Xenon Pharmaceuticals
Xenon Pharmaceuticals
XENE
NASDAQ
35.48
USD
0.00%
About
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE).
It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial.
Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 280.4K |
| Three Month Average Volume | 8.6M |
| High Low | |
| Fifty-Two Week High | 50.99 USD |
| Fifty-Two Week Low | 27.985 USD |
| Fifty-Two Week High Date | 01 Mar 2024 |
| Fifty-Two Week Low Date | 13 Nov 2023 |
| Price and Volume | |
| Current Price | 40.34 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -11.55% |
| Thirteen Week Relative Price Change | -1.00% |
| Twenty-Six Week Relative Price Change | -21.67% |
| Fifty-Two Week Relative Price Change | -17.41% |
| Year-to-Date Relative Price Change | -26.04% |
| Price Change | |
| One Day Price Change | 0.10% |
| Thirteen Week Price Change | 5.96% |
| Twenty-Six Week Price Change | -13.88% |
| Five Day Price Change | -1.03% |
| Fifty-Two Week Price Change | 3.49% |
| Year-to-Date Price Change | -12.42% |
| Month-to-Date Price Change | -6.47% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 12.31138 USD |
| Book Value Per Share (Most Recent Quarter) | 11.15468 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 12.31138 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 11.15468 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.20951 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.7268 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.7372 USD |
| Normalized (Last Fiscal Year) | -2.7268 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.7268 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.7372 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.7268 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.7372 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 8.46588 USD |
| Cash Per Share (Most Recent Quarter) | 9.53559 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.67386 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.68122 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.1499 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -569 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -684.26% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -743.72% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -683.58% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 25.14% |
| Tangible Book Value (5 Year) | 55.13% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -100.00% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 61.77% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -3.49% |
| EPS Change (Trailing Twelve Months) | -9.83% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -721,535,000 |
| Net Debt (Last Fiscal Year) | -638,082,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 24 |
| Current Ratio (Most Recent Quarter) | 23 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -150,944,000 |
| Free Cash Flow (Trailing Twelve Months) | -156,532,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -21.22% |
| Return on Assets (Trailing Twelve Months) | -25.38% |
| Return on Assets (5 Year) | -20.71% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -22.12% |
| Return on Equity (Trailing Twelve Months) | -26.71% |
| Return on Equity (5 Year) | -22.36% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -21.86% |
| Return on Investment (Trailing Twelve Months) | -26.37% |
| Return on Investment (5 Year) | -21.81% |